Hematologic toxicity (%) during subcutaneous first-line treatment with alemtuzumab in 38 patients with B-CLL who received more than 1 week of therapy
| . | NCI grading . | ||
|---|---|---|---|
| 0-I . | II-III . | IV . | |
| Anemia | 61 | 39 | 0 |
| Neutropenia | 26 | 53 | 216-150 |
| Thrombocytopenia | 84 | 11 | 5 |
| . | NCI grading . | ||
|---|---|---|---|
| 0-I . | II-III . | IV . | |
| Anemia | 61 | 39 | 0 |
| Neutropenia | 26 | 53 | 216-150 |
| Thrombocytopenia | 84 | 11 | 5 |
Occurred after a median time of 4 weeks (range, 1-8 weeks).